Key facts
- It has raised $21.3M across 1 recorded rounds; the latest was Later Stage VC ($6.3M) in May 2025.
- Notable investors include Buffalo Capital Partners, Excell Partners, Fosun Pharma, Jerry Jacobs, MEDA Angels — 10 tracked in total.
- MimiVax has filed 3 Form Ds with the SEC since 2015, most recently Jul 2024 ($5.8M sold to 16 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 10 names
- ·Watchlist + deal alerts for MimiVax
Funding rounds
1 roundsAbout MimiVax
Developer of immunotherapeutic vaccines and targeted therapies designed to control tumor growth and recurrence. The company's vaccines use surviving-targeting technology to target a cell-survival protein present in most cancers, enabling healthcare providers to disrupt cancer, cure patients and increase patient survival rates.
- Sector
- Healthcare
- HQ
- Buffalo, NY, United States
- Founded
- 2012
- Employees
- 3
- Website
- mimivax.com/
- Ownership
- Privately Held (backing)
MimiVax doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in MimiVax shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on MimiVax in its N-PORT filings yet. We sweep new filings monthly.